Exponent Balance Sheet Health
Financial Health criteria checks 6/6
Exponent has a total shareholder equity of $338.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $687.4M and $349.0M respectively. Exponent's EBIT is $116.7M making its interest coverage ratio -14. It has cash and short-term investments of $118.6M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -14x |
| Cash | US$118.55m |
| Equity | US$338.34m |
| Total liabilities | US$349.04m |
| Total assets | US$687.38m |
Recent financial health updates
No updates
Recent updates
EXPO: AI Failure Analysis Demand Will Support Higher Earnings Quality
Analysts have adjusted the 12 month price target on Exponent to $95 from $90, reflecting updated assumptions around revenue growth, profit margins, and the P/E multiple they are willing to apply to future earnings. Analyst Commentary Recent Street research on Exponent has centered on how much investors are willing to pay for the company’s future earnings, with price targets adjusted as analysts revisit revenue assumptions, profit margins, and the P/E multiple.
EXPO: AI Failure Analysis Work Will Sustain Premium P/E And Shareholder Returns
Analysts have trimmed their average price target for Exponent by $1.67 to reflect slightly lower fair value and profit margin assumptions, while still applying a relatively high future P/E multiple informed by recent mixed price target moves from JPMorgan and UBS. Analyst Commentary Recent Street research on Exponent reflects a mix of optimism about the business model and caution around valuation and near term execution, which is why price targets have moved in both directions.EXPO: AI Failure Analysis Work Will Support Margins And Shareholder Returns
Analysts have lifted their 12 month price target on Exponent by about $6 to around $92. This reflects updated expectations around revenue, margins and a slightly lower future P/E multiple following recent research updates from major firms.
EXPO: Buybacks And Dividend Increases Will Support Future Shareholder Returns
Analysts nudged their price target on Exponent higher by $4, citing slightly firmer growth and margin assumptions, along with a modestly lower future P/E outlook as key supports for the revised view. Analyst Commentary Recent research coverage around Exponent has centered on how much investors should be willing to pay for the company relative to its growth and margin profile.EXPO: Raised UBS Target And Buybacks Will Support Higher Future P/E
Analysts have raised their price target on Exponent by $4 to $85, citing updated assumptions that include slightly lower revenue growth, a modestly higher discount rate, improved profit margin expectations, and a higher future P/E multiple. Analyst Commentary Recent Street research around Exponent highlights a mix of optimism and restraint, with the latest published work focusing on valuation inputs, growth expectations, and how much investors are willing to pay for the stock through the P/E multiple.Exponent (NASDAQ:EXPO) Is Increasing Its Dividend To $0.31
Feb 09
EXPO: Bullish JPMorgan Initiation Will Support Confidence In Updated Fair Value Estimate
Analysts have raised their fair value estimate for Exponent from US$76.00 to US$81.00, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple in light of recent bullish Street research. Analyst Commentary Recent Street research, including a new bullish view from JPMorgan, has put more attention on how Exponent is priced and what could get in the way of the updated fair value estimate of US$81.00.EXPO: AI Failure Analysis Work Will Offset Automation Headwind Risks
Analysts have trimmed their price target on Exponent to US$90 from US$100, citing both the potential for increased AI driven failure analysis work and the offsetting risk that greater automation could reduce billable hours in consulting. Analyst Commentary Recent research points to a more balanced view on Exponent, with the reduced US$90 price target reflecting both potential upside from AI driven work and execution risks around automation in core consulting practices.EXPO: AI Failure Analysis Demand Will Support Future Consulting Engagements
Analysts have reduced their fair value estimate for Exponent to $90 from $100, citing a lower assumed future P/E multiple as they weigh the potential for AI-driven demand for failure analysis work against the risk that automation could reduce billable hours across the consulting sector. Analyst Commentary Recent commentary from bullish analysts centers on how AI adoption could shape Exponent's long term opportunity set, even as they factor in the risk that automation may cap billable hours across the consulting sector.What Exponent, Inc.'s (NASDAQ:EXPO) P/E Is Not Telling You
Jan 08EXPO: AI Failure Analysis Demand Will Outweigh Automation Efficiency Headwinds
Analysts have nudged their fair value estimate for Exponent higher to approximately $85.50 from $83.00 per share, citing the potential for AI driven demand in complex failure analysis work, while acknowledging that automation related efficiency gains could temper billable hours across the consulting industry. Analyst Commentary Bullish analysts highlight that the revised target still implies meaningful upside from current levels, even after a modest trim.EXPO: AI-Driven Demand Will Drive Future Engagements Despite Automation Headwinds
Analysts have revised Exponent's price target downward by $10 to $90 per share, citing potential opportunities from AI-driven engagements as well as industry headwinds related to automation efficiencies. Analyst Commentary Following the recent revision to Exponent's price target, analysts have highlighted both opportunities and risks facing the company in today's evolving market landscape.EXPO: AI-Driven Client Demand Will Offset Automation Concerns In Consulting
Exponent’s analyst price target has been reduced by $10 to $90, as analysts cite ongoing automation concerns that could impact the consulting sector. They also note potential opportunities from increased AI-driven client demand.Exponent, Inc. Just Beat EPS By 8.5%: Here's What Analysts Think Will Happen Next
Nov 02EXPO: Increased Buyback Will Drive Shareholder Returns In Coming Quarters
Narrative Update: Exponent Analyst Price Target Adjustment Analysts have lowered their price target for Exponent from $88 to $83. This change reflects updated expectations for revenue growth and profitability margins moving forward.Returns On Capital At Exponent (NASDAQ:EXPO) Have Stalled
Oct 06A Look At The Fair Value Of Exponent, Inc. (NASDAQ:EXPO)
Jul 30When Should You Buy Exponent, Inc. (NASDAQ:EXPO)?
Jul 14Exponent (NASDAQ:EXPO) Knows How To Allocate Capital
Jun 28Subdued Growth No Barrier To Exponent, Inc.'s (NASDAQ:EXPO) Price
May 27Is Exponent, Inc. (NASDAQ:EXPO) Potentially Undervalued?
Apr 06Return Trends At Exponent (NASDAQ:EXPO) Aren't Appealing
Mar 22Exponent: A Unique Dividend Contender That Is Valued At A Premium
Mar 10Exponent's (NASDAQ:EXPO) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 13Exponent, Inc.'s (NASDAQ:EXPO) Intrinsic Value Is Potentially 34% Above Its Share Price
Jan 30Risks To Shareholder Returns Are Elevated At These Prices For Exponent, Inc. (NASDAQ:EXPO)
Dec 28Here's What To Make Of Exponent's (NASDAQ:EXPO) Decelerating Rates Of Return
Dec 10Exponent's (NASDAQ:EXPO) Earnings Seem To Be Promising
Nov 08Estimating The Intrinsic Value Of Exponent, Inc. (NASDAQ:EXPO)
Oct 13
Operational Efficiency And Tactical Investments Set To Propel Future Profitability And Revenue Growth
Exponent's strategic management and operational efficiency improvements are poised to enhance future profitability and earnings potential.Exponent, Inc.'s (NASDAQ:EXPO) Share Price Not Quite Adding Up
Aug 20Exponent, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Jul 28Calculating The Fair Value Of Exponent, Inc. (NASDAQ:EXPO)
Jul 12Exponent: Slow Growth Ahead Makes The Valuation Stretched
Jul 08Many Would Be Envious Of Exponent's (NASDAQ:EXPO) Excellent Returns On Capital
Jun 18Financial Position Analysis
Short Term Liabilities: EXPO's short term assets ($340.9M) exceed its short term liabilities ($142.2M).
Long Term Liabilities: EXPO's short term assets ($340.9M) exceed its long term liabilities ($206.8M).
Debt to Equity History and Analysis
Debt Level: EXPO is debt free.
Reducing Debt: EXPO has not had any debt for past 5 years.
Debt Coverage: EXPO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: EXPO has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/01 02:59 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2026/04/03 |
| Annual Earnings | 2026/01/02 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Exponent, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Foresi | Brean Capital Historical (Janney Montgomery) |
| Alexis Huseby | D.A. Davidson & Co. |
| Tomohiko Sano | J.P. Morgan |